tiprankstipranks
Trending News
More News >

Y-mAbs Therapeutics sees 2025 revenue $75M-$90M, consensus $82.49M

Cash and cash equivalents are anticipated to be sufficient to fund operations as currently planned into 2027.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1